DNTH

Dianthus Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 4/10
  • Value↓ 0/10
Dianthus Therapeutics sales and earnings growth
DNTH Growth
Neutral
  • Revenue Y/Y↓ -85.21%
  • EPS Y/Y↓ -46.02%
  • FCF Y/Y↓ -43.44%
Dianthus Therapeutics gross and profit margin trends
DNTH Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -12998.50%
  • ROIC 5Y↓ -83.58%
Dianthus Therapeutics net debt vs free cash flow
DNTH Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Dianthus Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks